FindTrial
Sign In

To Study The Predictors of Lymphedema in Ipsilateral Arm in Patients treated with Modified Radical Mastectomy for Breast Cancer

To Study The Predictors of Lymphedema in Ipsilateral Arm in Patients treated with Modified Radical Mastectomy for Breast Cancer -A Prospective observational study - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2023/08/056411
Enrollment
150
Registered
2023-08-11
Start date
Unknown
Completion date
Unknown
Last updated
2023-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C509- Malignant neoplasm of breast of unspecified site

Interventions

Intervention1: NIL: NIL Control Intervention1: NIL: NIL

Sponsors

AIIMS RISHIKESH
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.All Female Patients >18 years of age with Biopsy proven Infiltrating Ductal Carcinoma (Adenocarcinoma) Breast cancer who underwent Modified Radical Mastectomy 2.Giving Informed consent for being included in the study

Exclusion criteria

Exclusion criteria: Preexisting Lymphedema of the Ipsilateral arm. Axillary Vein thrombosis Metastatic Breast cancer Bilateral breast cancer Recurrent breast cancer

Design outcomes

Primary

MeasureTime frame
To study the Patient factors & Tumour factors as Predictors of Arm Lymphedema in breast cancer patients undergoing Modified Radical Mastectomy Timepoint: To study the Patient factors & Tumour factors as Predictors of Arm Lymphedema in breast cancer patients undergoing Modified Radical Mastectomy Lymphedema/arm size will be recorded at baseline 1 month, 3 months and 6 months—

Secondary

MeasureTime frame
To find the Prevalence of Arm Lymphedema in patients who have undergone Modified Radical Mastectomy. Timepoint: at end of study, 18 months;Compare prevalence of Arm Lymphedema in patients who have undergone Modified Radical Mastectomy among different stages of Breast cancer. Timepoint: at end of study, 18 months—

Countries

India

Contacts

Public ContactMOHD OZAIR KHAN

AIIMS RISHIKESH

farhanul1973huda@gmail.com9997533211

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026